J 2008

Genetic variations and plasma levels of the Gelatinase A (matrix metalloproteinase-2) and Gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy

BERÁNEK, Michal, Petr KOLÁŘ, Svatava TSCHÖPLOVÁ, Kateřina KAŇKOVÁ, Anna VAŠKŮ et. al.

Basic information

Original name

Genetic variations and plasma levels of the Gelatinase A (matrix metalloproteinase-2) and Gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy

Name in Czech

Genetic variations and plasma levels of the Gelatinase A (matrix metalloproteinase-2) and Gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy

Authors

BERÁNEK, Michal (203 Czech Republic), Petr KOLÁŘ (203 Czech Republic, belonging to the institution), Svatava TSCHÖPLOVÁ (203 Czech Republic, belonging to the institution), Kateřina KAŇKOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Anna VAŠKŮ (203 Czech Republic, belonging to the institution)

Edition

Molecular Vision, 2008, 1090-0535

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30202 Endocrinology and metabolism

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.464

RIV identification code

RIV/00216224:14110/08:00024690

Organization unit

Faculty of Medicine

UT WoS

000257890500002

Keywords in English

retinopathy; MMP; diabetes

Tags

Diabetes, MMP, retinopathy

Tags

International impact, Reviewed
Změněno: 29/10/2012 10:22, prof. MUDr. Petr Kolář, Ph.D.

Abstract

ORIG CZ

V originále

Purpose: The matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. Methods: Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined in a study comprising three groups of Caucasian subjects (total n=490, diabetics with and without PDR and non-diabetics). The plasma levels of the MMP-2 and -9 proteins were analyzed by ELISA. Results: Neither MMP-2 nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differed significantly between groups. Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were significantly higher in carriers of either the -1306CC and CT genotypes (p=0.009) or CGCG haplotype (p=0.043). Conclusions: These findings indicate that genotype- and haplotype-specific effects on the MMP-2 gene expression corresponding with its plasma levels may contribute to the susceptibility to PDR.

In Czech

Purpose: The matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. Methods: Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined in a study comprising three groups of Caucasian subjects (total n=490, diabetics with and without PDR and non-diabetics). The plasma levels of the MMP-2 and -9 proteins were analyzed by ELISA. Results: Neither MMP-2 nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differed significantly between groups. Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were significantly higher in carriers of either the -1306CC and CT genotypes (p=0.009) or CGCG haplotype (p=0.043). Conclusions: These findings indicate that genotype- and haplotype-specific effects on the MMP-2 gene expression corresponding with its plasma levels may contribute to the susceptibility to PDR.

Links

GP303/05/P523, research and development project
Name: Vztah genetických polymorfizmů v kandidátních genech účastnících se procesu angiogeneze k proliferativní retinopatii u diabetes mellitus 2. typu
Investor: Czech Science Foundation, Relationship between genetic variability in candidate genes involved in angiogenesis and proliferative retinopathy in Type 2 diabetes mellitu
Displayed: 17/11/2024 12:55